1.Impurity limit test of raw material of ciprofloxacin by high performance capillary electrophoresis
Academic Journal of Second Military Medical University 2000;0(10):-
Objective: To develop a high performance capillary electrophoresis(HPCE) method for the impurity limit test of raw material of ciprofloxacin. Methods: An optimal method was established by studying on pH value, sampling time and other electrophoretic conditions. Results: The RSD of migration time was 0.23% and of the peak area was 2.49%. The limit of detection was 1.21 ?mol/L. The impurity profile and content was consistent with the dilution of sample concentration. Conclusion: HPCE method proves to be suitable for impurity limit test of raw material of ciprofloxacin. [
2.Preliminary study of neoadjuvant plus chemotherapy combined with concurrent chemoradiotherapy for locally advanced giant cervical cancer
Hua YANG ; Lichun WEI ; Ying ZHANG ; Jianjun ZHANG ; Yutian YIN ; Yan ZHOU ; Mei SHI
Chinese Journal of Radiation Oncology 2021;30(4):372-375
Objective:To preliminarily investigate the efficacy and safety of bevacizumab plus neoadjuvant chemotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced giant cervical cancer (LACC).Methods:Twenty-four patients with LACC who were treated with bevacizumab combined with neoadjuvant chemotherapy were assigned into the study group, and 30 patients receiving neoadjuvant chemotherapy in phase Ⅱ clinical trial (ChiCTR-TRC-11001832) were allocated in the control group. The survival rate was calculated by the Kaplan- Meier method, and the significance of differences between the variables was determined by the log-rank test. Results:The tumor volumes were (1.64±23.15) cm 3 and (12.83±15.08)( P=0.037), and the complete remission (CR) rates were calculated as 45.8% and 13.3%( P=0.004) in the study and control groups after neoadjuvant chemotherapy. The tumor volumes were (0±1.5) cm 3 and (1.00±10.63) cm 3( P=0.022) and the CR rates were 70% and 50%( P=0.009) in the study and control groups before afterloading treatment. The median follow-up was 24.6(9.3-101.7) months. The 1-and 2-year overall survival rates were 96%, 96% and 90%, 71%( P=0.110), the recurrence-free survival rates was 96%, 96% and 97%, 89%( P=0.512), and the distant metastasis-free survival rates were 96%, 88% and 83%, 80%( P=0.297) in the study and control groups, respectively. Adverse reactions were acceptable in both groups. Conclusion:Bevacizumab combined with neoadjuvant chemotherapy can significantly reduce the tumor volume, improve the tumor CR rate and yield tolerable adverse reactions.